| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sunshine Biopharma Inc.$1.43
-0.1 (-6.54%)
B 71Pipeline Score Undervalued Pharma · Clinical
Market Cap
2.41 M
EPS
-1.30
P/E Ratio
-
Value Trade
2.20 M
SEC Financials
Q1 2026Dilution Risk
Revenue
8.09 M
R&D Expenses
31.72 K
Operating CF
-2.07 M
Total Assets
27.93 M
Total Liabilities
6.41 M
Equity
21.52 M
D/E Ratio
12,345
4.63 %
Week
-51.38 %
1 Month
-58.86 %
3 Month
-66.11 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
6.91 M
Monthly Burn
691.00 K
Runway
7.5 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
63.56 K
52 Week Range
0.28 - 2.43
% held by Insiders
8.06 %
% held by Institutions
4.5 %
Enterprise Value
-3.75 M
Total Shares
2.12 M
Short %
2.85 %
Float Shares
1.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sunshine Biopharma Inc.
156Total events
1Upcoming
27Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 1
TBD
T3Preclinical PoC
Subscribe to view catalyst details
Event history 2
TBD
▲Patent GrantedIP / Competition
Subscribe to view catalyst details
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
B71
Pipeline Score $36M
Pipeline ValueUndervalued
Valuation Signal68
Drugs Scored15.0x
rNPV / MCap Top 95%
Micro Cap (rank 47 of 913)
Percentile RankSunshine Biopharma Inc. holds a solid B-grade pipeline (71/100), with $19.8B risk-adjusted pipeline value, led by HEC169096 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HEC169096 Small molecule | Advanced Solid Tumor | Phase 1 | NCT05451602 | 5% | $4.2B | RECRUITING | 456 | VERY_FAST | D (20) | Aug 30, 2027 | - | LOW Jul 5, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SBFM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SBFM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SBFM▼ -19.8%on this news
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
Sunshine Biopharma has announced the issuance of U.S. Patent No. 12,624,066 B2, which covers its innovative compounds aimed at treating coronavirus infections. The patent protects small molecule inhibitors that target a viral enzyme crucial for immune suppression. This development is seen as a significant milestone for the company, emphasizing its commitment to addressing current and future viral threats.
Read more →SBFM▼ -13.7%on this news· ran to -28% by day 1
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering FORT LAUDERDALE, FL, MAY 18, 2026 (ACCESS NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: SBFM) (the "Company"), a pharmaceutical company offering a
Sunshine Biopharma Inc. has announced the pricing of a $6.0 million public offering, consisting of 12,000,000 Common Units at a price of $0.50 each. The offering is expected to close on May 19, 2026, pending customary closing conditions. The company plans to use the net proceeds to support its general corporate purposes and working capital. Additionally, Sunshine Biopharma is currently working on developing life-saving medicines in various therapeutic areas, including oncology and antivirals.
Read more →SBFM▲ +11.5%on this news
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year FORT LAUDERDALE, FL / ACCESSWIRE /
Sunshine Biopharma (SBFM) reported a fiscal 2025 revenue of $36.3 million, marking a 4.1% increase from 2024. The company has launched nine new generic drugs and continues to advance its proprietary antiviral research. Despite an increased net loss of $5.98 million due to higher general and administrative expenses and an impairment charge, management is optimistic about future growth opportunities and profitable operations. Cost-reduction strategies are being implemented to focus on achieving profitability in the coming years.
Read more →SBFM▼ -5%on this news
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year FORT LAUDERDALE, FL / ACCESSWIRE /
Sunshine Biopharma Inc. reported a significant 18% increase in revenues for the first quarter of 2025, compared to the previous year, showcasing strong financial results. CEO Dr. Steve Slilaty emphasized the company's commitment to innovation and sustainable growth as it aims to expand its product pipeline. Despite positive revenue growth, the company recorded a net loss of $1,179,771, albeit improved from the prior year's loss. Sunshine Biopharma is also gearing up to launch new medications, including NIOPEG, a biosimilar for cancer patients.
Read more →SBFM▼ -18.2%on this news· ran to -36% by day 3
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules FORT LAUDERDALE, FL, APRIL 2, 2025 (ACCESS NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: SBFM) (the "Comp
Sunshine Biopharma Inc. has announced a registered direct offering of approximately $2.46 million, selling common stock at $2.07 per share. The offering is expected to close around April 3, 2025, pending customary conditions. Proceeds will be utilized for general corporate purposes and working capital. This transaction reflects Sunshine Biopharma's ongoing efforts to strengthen its financial position as it continues developing various life-saving therapeutic products.
Read more →SBFM▲ +8.9%on this newsshared move
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year FORT LAUDERDALE, FL / ACCESSWIRE /
Sunshine Biopharma Inc. (SBFM) reported a significant revenue increase, reaching $34.9 million in fiscal 2024, a 45% rise compared to the previous year. The company successfully launched 13 new generic prescription drugs and received approval for the oncology drug NIOPEG. Additionally, Sunshine Biopharma published research showcasing a new Coronavirus PLpro inhibitor with strong efficacy. Despite these successes, the company faced a net loss of $5.1 million, reflecting rising administrative costs.
Read more →SBFMSUNSHINE BIOPHARMA ANNOUNCES THE APPOINTMENT OF NEW CHIEF COMMERCIAL OFFICER FORT LAUDERDALE, FL / ACCESSWIRE /
Sunshine Biopharma Inc. (SBFM) has appointed Mr. Michel Roy as its new Chief Commercial Officer, effective immediately. Mr. Roy, who has over 20 years of experience in the pharmaceutical industry, will oversee the company's commercial strategy, including sales and marketing. The transition comes as Sunshine Biopharma prepares to launch additional drugs in 2025, enhancing its market presence and growth trajectory. CEO Dr. Steve Slilaty expressed confidence in Mr. Roy's ability to contribute significantly to the company's objectives.
Read more →SBFM▼ -6.3%on this news
SUNSHINE BIOPHARMA REPORTS 2024 THIRD QUARTER RESULTS: YEAR-TO-DATE REVENUES UP 54% FORT LAUDERDALE, FL / ACCESSWIRE /
Sunshine Biopharma Inc. reported significant growth in its 2024 third quarter financial results, with gross revenues reaching $8,435,178, marking a 42% increase from the previous year. Year-to-date revenues have surged by 54%, driven primarily by new product launches and enhanced marketing efforts. Despite the revenue increase, the company faced a net loss of $1,197,803 for the quarter. The management emphasizes their strategy of pursuing profitability while continuing to expand their product offerings in oncology and antivirals.
Read more →SBFM▲ +5.8%on this news
SUNSHINE BIOPHARMA REPORTS 2024 SECOND QUARTER RESULTS: SECOND QTR REVENUES UP 67%, YTD REVENUES UP 61% FORT LAUDERDALE, FL / ACCESSWIRE /
Sunshine Biopharma, Inc. has reported substantial growth in its financial performance for the second quarter of 2024, with revenues reaching $9.3 million, a 67% increase compared to the same quarter last year. Year-to-date revenues also saw a significant rise of 61%, attributed to new product launches and expanded marketing efforts. However, the company continues to face challenges, reporting a net loss despite these revenue gains. CEO Dr. Steve Slilaty expressed confidence in the company's strategies for achieving profitability and sustainable growth.
Read more →SBFM▼ -17.8%on this news
SUNSHINE BIOPHARMA REPORTS 2024 FIRST QUARTER RESULTS: REVENUES UP 54% NEW YORK, NY / ACCESSWIRE /
Sunshine Biopharma, Inc. (SBFM) announced its financial results for the first quarter of 2024, reporting a 54% increase in gross revenues, reaching $7,541,046 compared to $4,894,053 in Q1 2023. The growth is attributed to new product launches and expanded marketing efforts by its subsidiary, Nora Pharma Inc. Despite the revenue growth, the company continues to report a net loss, although it has decreased from the previous year. Sunshine Biopharma is preparing to launch additional drugs, including a biosimilar to NEULASTA, furthering its commitment to drug development in oncology and antiviral treatments.
Read more →SBFMSUNSHINE BIOPHARMA REPORTS OPERATING RESULTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 Sales Grew at an Average Rate of 14% Per Quarter During the Year NEW YORK, NY / ACCESSWIRE /
Sunshine Biopharma Inc. reported its fiscal year 2023 operating results, highlighting a strong sales growth of 14% per quarter. Total sales reached over $24 million with a notable increase in gross profit compared to the previous year. Despite these positive trends, the company still faced a net loss, albeit significantly reduced from 2022. Looking ahead, Sunshine Biopharma aims to expand its drug offerings and continue its growth trajectory into 2024 and beyond.
Read more →SBFMSunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering NEW YORK, FEBRUARY 13, 2024 -- Sunshine Biopharma, Inc. (NASDAQ: SBFM) (the "Company"), a pharmaceutical company offering and resea
Sunshine Biopharma, Inc. has announced a $10 million underwritten public offering consisting of 71,428,571 units priced at approximately $0.14 per unit. The offering is expected to close on or about February 15, 2024, subject to customary closing conditions. The proceeds from this offering will be utilized for general corporate purposes and working capital. Aegis Capital Corp. is acting as the sole book-running manager for this offering, indicating a structured approach to capital raise. Sunshine Biopharma has a growing portfolio of prescription drugs and is actively developing proprietary treatments.
Read more →SBFMSunshine Biopharma Moves Principal Office to New York City
Sunshine Biopharma, Inc. has announced the relocation of its headquarters from Montreal to New York City, which is expected to enhance its operational capabilities and market presence. The new office is located at 1177 Avenue of the Americas, while the company will retain a satellite office in Canada. Sunshine Biopharma aims to expand its generic drug offerings and is involved in developing new therapies for liver cancer and COVID-19. The move reflects the company's strategic growth initiatives in the competitive pharmaceutical landscape.
Read more →SBFMSUNSHINE BIOPHARMA RECEIVES 180-DAY EXTENSION
Sunshine Biopharma Inc. has received a 180-day extension from Nasdaq to meet the minimum $1.00 bid price requirement for its common stock, extending the deadline to March 18, 2024. This extension allows the company time to regain compliance without immediate impact on its stock listing or trading. The firm plans to address this compliance issue, potentially through a reverse stock split, while also expanding its portfolio of generic drugs and continuing its proprietary drug development across several indications.
Read more →SBFMSunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%
Sunshine Biopharma Inc. reported a remarkable 3,600% increase in gross revenues for the second quarter of 2023, totaling $5.56 million compared to the same quarter in 2022. This significant growth can be attributed to the acquisition of Nora Pharma Inc., which has enhanced the company's product portfolio. Additionally, the revenues reflect a 13.6% increase from the first quarter of the year. The company remains committed to expanding its generic prescription drug offerings and advancing its proprietary drug development programs.
Read more →SBFMSUNSHINE BIOPHARMA REPORTS 2023 SECOND QUARTER
Sunshine Biopharma Inc. (NASDAQ: SBFM) reported a substantial increase in gross revenues of $5,560,865 for the second quarter of 2023, marking a 3,600% rise from the previous year. This growth was primarily attributed to the acquisition of Nora Pharma Inc., which added numerous generic prescription drugs to its portfolio. The company is optimistic about continued growth, with plans to expand its product offerings significantly over the next 18 months. CEO Dr. Steve Slilaty expressed enthusiasm about the current and future financial performance of the company.
Read more →SBFMSunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market
Sunshine Biopharma has completed a $5 million private placement with a healthcare-focused institutional investor. The company issued nearly 6 million units at a price of $0.84 each, which includes shares and non-tradable warrants. Sunshine Biopharma aims to expand its generic drug offerings and continues its proprietary drug development program.
Read more →SBFMSunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market
Sunshine Biopharma Inc. has announced a $5 million private placement agreement with a healthcare-focused institutional investor. The offering will consist of nearly 6 million units priced at $0.84 each, including warrants. The transaction is expected to close around May 16, 2023, pending customary conditions. This move supports the company's expansion plans and ongoing drug development efforts.
Read more →SBFMof therapeutic areas including oncology and antivirals today announced that it has filed its 2023 first quarter report.
Sunshine Biopharma Inc. (NASDAQ: SBFM) has reported its 2023 first quarter results, revealing gross revenues of $4,894,053, a remarkable increase of over 2,100% year-over-year. This spike in revenue is primarily attributed to the sales from their recently acquired subsidiary, Nora Pharma Inc. The company plans to expand its generic drug offerings and continues to advance its proprietary drug development program targeting various cancers and COVID-19. CFO Camille Sebaaly expressed optimism for ongoing growth in 2023 and beyond.
Read more →SBFMSunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%
Sunshine Biopharma Inc. reported a remarkable increase in its 2023 first quarter revenues, reaching $4,894,053, which reflects a growth of over 2,100% compared to 2022. This surge is primarily attributed to the sales from its recently acquired subsidiary, Nora Pharma Inc. Additionally, the company has introduced a stock repurchase program and secured research agreements aimed at advancing its anticancer and COVID-19 treatment initiatives. Sunshine Biopharma is looking to expand its range of generic pharmaceuticals and enhance its proprietary drug development efforts.
Read more →SBFMSunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update
Sunshine Biopharma Inc. reported its financial results for the year ended December 31, 2022, showcasing a substantial increase in sales and a strengthened balance sheet. The company highlighted its acquisition of Nora Pharma, which has expanded its range of generic prescription drugs available in Canada. Additionally, Sunshine Biopharma is advancing its drug development efforts, specifically in oncology and COVID-19 treatments, through collaborations with leading institutions. The CFO expressed optimism about the company's future growth and shareholder value.
Read more →SBFMReport.
Sunshine Biopharma Inc. has secured an exclusive worldwide license from the University of Arizona for PLpro inhibitors targeting SARS-CoV-2. This collaboration, ongoing since February 2022, aims to develop new treatments against COVID-19. The licensed technology is designed to inhibit a specific protease associated with the virus, potentially addressing treatment resistance. The company is optimistic about advancing its COVID-19 treatment pipeline as a result of this milestone.
Read more →SBFMSunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment
Sunshine Biopharma has signed an exclusive worldwide license agreement with the University of Arizona, granting it rights to develop PLpro protease inhibitors targeting COVID-19. This collaboration, which has been ongoing since February 2022, aims to mitigate severe illness caused by SARS-CoV-2. The licensed technology pertains to small molecules effective in inhibiting the second coronavirus protease. Sunshine Biopharma also highlighted its ongoing drug development initiatives, including its COVID-19 treatment pipeline.
Read more →SBFMSIGNS RESEARCH AGREEMENT WITH THE JEWISH GENERAL HOSPITAL TO ADVANCE THE DEVELOPMENT OF Adva-27a ANTICANCER COMPOUND
Sunshine Biopharma Inc. has signed a research agreement with the Jewish General Hospital in Montreal to advance the development of its anticancer compound, Adva-27a. This collaboration will focus on IND-enabling studies, with the potential to transition to a Phase I clinical trial based on successful results. The project will be supervised by Dr. Gerald Batist, a prominent figure in oncology. The agreement reflects confidence in the efficacy of Adva-27a in targeting multidrug resistant cancer cells from various cancers.
Read more →SBFMSunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound
Sunshine Biopharma Inc. has signed a research agreement with the Jewish General Hospital to advance the development of its Adva-27a anticancer compound through IND-enabling studies. This collaboration is set to be directed by Dr. Gerald Batist, a prominent figure in oncology. The agreement marks a significant step towards potentially conducting a Phase I clinical trial, contingent on favorable research outcomes. Adva-27a has demonstrated effectiveness against various types of multidrug resistant cancer cells, including those from pancreatic cancer and breast cancer.
Read more →SBFMSunshine Biopharma Announces Share Repurchase Program
Sunshine Biopharma Inc. has announced a share repurchase program authorized by its board, allowing the company to buy back up to $2 million of its common stock. This move reflects the company's belief in enhancing shareholder value amid a favorable market environment and a robust balance sheet worth $40.5 million. The repurchase will be executed at management's discretion and might depend on market conditions and regulatory frameworks. Sunshine Biopharma continues its drug development initiatives, especially in oncology and antiviral treatment.
Read more →SBFMSunshine Biopharma’s Annual Letter to Shareholders
MONTREAL, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today issued a letter to shareholders from Dr. Steve S
Read more →SBFMSunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project
MONTREAL, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaborat
Read more →SBFMBiopharma ANNOUNCES THE ACQUISITION OF NORA PHARMA,
Biopharma ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE Montreal, Canada - (GLOBE NEWSWIRE) - Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral dr
Read more →SBFMSunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue
MONTREAL, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has completed the acquisition of all the outstanding
Read more →SBFMSunshine Biopharma Files Its Second Quarter Report With the SEC
MONTREAL, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed its 2022 second quarter report
Read more →SBFMSunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona
MONTREAL, July 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has
Read more →SBFMSunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market
MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previo
Read more →SBFMSunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market
MONTREAL, April 26, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it
Read more →SBFMSunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a provisional patent applicat
Read more →SBFMSunshine Biopharma’s Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells
MONTREAL, April 05, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that two of its newly designed mRNA molecules a
Read more →SBFMSunshine Biopharma, Inc. 6500 Trans-Canada Highway 4th Floor Pointe-Claire, Quebec, Canada H9R0A5
Sunshine Biopharma, Inc. 6500 Trans-Canada Highway Pointe-Claire, Quebec, Canada H9R0A5 Ladies and Gentlemen: Reference is hereby made to the warrants ("Warrants") to purchase shares of common stock, dated March 14, 2022, issued by Sunshine Biopharma, Inc. (the "Company").
Read more →SBFMSunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market
MONTREAL, March 14, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previo
Read more →SBFMSunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market
MONTREAL, March 10, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it
Read more →SBFMSunshine Biopharma Expands Anti-Coronavirus Drug Development Program By Signing A Collaboration Agreement With The University Of Arizona
MONTREAL, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has
Read more →SBFMSunshine Biopharma, Inc. Announces Closing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
MONTREAL, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced today the clos
Read more →SBFMSunshine Biopharma, Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market
MONTREAL, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced today the pric
Read more →SBFMSunshine Biopharma Inc. (OTC Markets: SBFM) ` To the extent that statements in this presentation are not strictly historical, including statements as to revenue projections, future estimates, plans, programs, forecasts,
Sunshine Biopharma Inc. (OTC Markets: SBFM) ` To the extent that statements in this presentation are not strictly historical, including statements as to revenue projections, future estimates, plans, programs, forecasts, objectives, assumptions, expectations, marketing and sales
Read more →SBFMAnnounces $1,361,000 in Debt Reduction
Announces $1,361,000 in Debt Reduction Montreal, Quebec, Canada - (GLOBE NEWSWIRE) - Sunshine Biopharma Inc. (OTC PINK: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that on Decembe
Read more →SBFMSunshine Biopharma Announces $1,361,000 in Debt Reduction
MONTREAL, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that on December 20, 2021, the Company issued 2,904,833 sha
Read more →SBFMIndependent Directors Added as Part of Company's
EXPANDS BOARD OF DIRECTORS Independent Directors Added as Part of Company's Application Process to Uplist to Nasdaq Montreal, Quebec, Canada - (GLOBE NEWSWIRE) - Sunshine Biopharma Inc. (OTC PINK: "SBFM"), a pharmaceutical company focused on the research, development and comm
Read more →SBFMSunshine Biopharma Expands Board of Directors
MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has expanded its board of directors from three to f
Read more →SBFMSunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a patent application for a potential new
Read more →SBFMSunshine Biopharma’s Coronavirus Treatment Anticipated to be Effective Against Delta and the Other Variants of Concern
MONTREAL, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC Pink: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it mapped the mutations found in Delta and the other va
Read more →SBFMSunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
MONTREAL, July 27, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, is pleased to announce that we have opened an official company Twitter acco
Read more →SBFMSunshine Biopharma Receives $0.9 Million in Additional Funding From RB Capital
MONTREAL, July 20, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received additional funding from RB Capital Par
Read more →SBFMSunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer
MONTREAL, July 08, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has succeeded in inhibiting the activity of Nrf2 us
Read more →SBFMSunshine Biopharma Mice Study for COVID-19 Treatment Progressing as Planned
MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today confirmed that its COVID-19 mice study currently underway at the Univ
Read more →SBFMSunshine Biopharma’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types
MONTREAL, May 25, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has elucidated the mechanism of action of Adva-27a,
Read more →SBFMSunshine Biopharma Eliminates $250,000 in Variable Rate Convertible Debt and Provides an Update on Status of OTCQB Uplisting
MONTREAL, May 20, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has paid off $250,000 in variable rate convertible d
Read more →SBFMSunshine Biopharma Reports Improved Cash Position in 2021Q1 Filing
MONTREAL, May 13, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs, announced that it has filed its 2021 first quarter report. The Report shows
Read more →SBFMSunshine Biopharma Upgrades COVID-19 Provisional Patent Application to Full PCT Application
MONTREAL, May 04, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has timely filed a nonprovisional patent application
Read more →SBFMSunshine Biopharma Reports Favorable MTD Results for COVID-19 Treatment
MONTREAL, April 19, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed a Maximum Tolerated Dos
Read more →SBFMSunshine Biopharma Reaches $2,000,000+ Financing for Coronavirus Treatment
MONTREAL, March 23, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received a total of $2,054,000 to date from th
Read more →SBFMSunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a in Europe Until 2033
MONTREAL, March 11, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a “Notice of Allowance” from the Europ
Read more →SBFMSunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC Testing
MONTREAL, March 04, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received shipment of a new batch of Adva-27a f
Read more →SBFMSunshine Biopharma Launches eCommerce Store for Its Science-Based Nutritional Supplements
MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a leader in nutrition research and development today unveiled its new eCommerce website, Nutrition.SushineBiopharma.com. The site boasts over 20 products ranging from essential amino acids an
Read more →SBFMSUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP
SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG Canada (ACCESSWIRE) Sunshine Biopharma Inc. (OTC Markets: SBFM ), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs t
Read more →SBFMSUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING
SUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT Quebec, Canada -- (ACCESSWIRE) -- Sunshine Biopharma Inc. (OTC Markets: SBFM ), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, to
Read more →SBFMSUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A
SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A CORONAVIRUS COVID-19 TREATMENT Canada (ACCESSWIRE) Sunshine Biopharma Inc. (OTC Pink Sheets: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressi
Read more →SBFMSUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9 IS NOW
SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9 IS NOW AVAILABLE ON AMAZON.CA Quebec, Canada (ACCESSWIRE) Sunshine Biopharma, Inc. (OTC Markets: SBFM ) today announced that its recently launched micronutrients supplement, Essential now available on www.Amazon.ca. 14, 2018, He
Read more →SBFMAverage Prices (VWAP) of the Company's Common Stock for the 10
SUNSHINE BIOPHARMA ANNOUNCES $10 MILLION EQUITY Quebec, Canada (ACCESSWIRE) Sunshine Biopharma, Inc. (OTCMKTS: SBFM) (the Company or Sunshine ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms
Read more →SBFMSUNSHINE BIOPHARMA COMPLETES THE ACQUISITION OF ATLAS
SUNSHINE BIOPHARMA COMPLETES THE ACQUISITION OF ATLAS Quebec, Canada -- (ACCESSWIRE) On January 1, 2018, Sunshine Biopharma Inc. (OTCBB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of
Read more →SBFMReport ) placing the en bloc Fair Market Value of the
SUNSHINE BIOPHARMA ENTERS INTO AN INVESTMENT BANKING AGREEMENT WITH JITNEY TRADE TO RAISE UP TO $10 MILLION FOR CLINICAL TRIALS OF Adva-27a ANTICANCER DRUG Quebec, Canada -- (ACCESSWIRE) -- Sunshine Biopharma Inc. (OTC Markets: SBFM ), a pharmaceutical company focused on the
Read more →SBFM( MNP ) was retained to provide a Valuation Report (the
SUNSHINE BIOPHARMA RELEASES RESULTS OF INDEPENDENT Quebec -- (ACCESSWIRE) -- Sunshine Biopharma Inc. (OTC Markets: SBFM) is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's
Read more →SBFMSUNSHINE BIOPHARMA ELIMINATES THE DEBT OBLIGATIONS ASSOCIATED WITH THE RECENTLY ACQUIRED PATENTS FOR IT'S Adva-27a ANTICANCER COMPOUND
SUNSHINE BIOPHARMA ELIMINATES THE DEBT OBLIGATIONS ASSOCIATED WITH THE RECENTLY ACQUIRED PATENTS FOR IT'S Adva-27a ANTICANCER COMPOUND Montreal, Quebec -- (MARKETWIRE) -- Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and com
Read more →SBFMSUNSHINE BIOPHARMA ACQUIRES ALL REMAINING WORLDWIDE PATENTS FOR ITS Adva-27a ANTICANCER COMPOUND
SUNSHINE BIOPHARMA ACQUIRES ALL REMAINING WORLDWIDE PATENTS FOR ITS Adva-27a ANTICANCER COMPOUND Montreal, Quebec, Canada -- (MARKETWIRE) -- Sunshine Biopharma Inc. (OTCQB: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of drugs for
Read more →SBFMSUNSHINE BIOPHARMA ACQUIRES THE US PATENT FOR ITS ANTICANCER COMPOUND, Adva-27a
SUNSHINE BIOPHARMA ACQUIRES THE US PATENT FOR ITS ANTICANCER COMPOUND, Adva-27a Montreal, Quebec, Canada -- (MARKETWIRED) -- Sunshine Biopharma Inc. (OTCQB: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of
Read more →SBFMSUNSHINE BIOPHARMA ANNOUNCES THAT THE INITIAL MANUFACTURING SAMPLE
SUNSHINE BIOPHARMA ANNOUNCES THAT THE INITIAL MANUFACTURING SAMPLE OF ITS ANTICANCER COMPOUND Adva-27a MEETS BIOLOGICAL SPECIFICATIONS PAVING THE WAY FOR CLINICAL TRIALS Montreal, Quebec, Canada -- (MARKETWIRED) -- Sunshine Biopharma Inc. (OTCQB: "SBFM"), a pharmaceutical comp
Read more →SBFMSunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering Adva-27a Anticancer Compound in India
MONTREAL, March 24, 2015 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTCQB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that a "Notice of Allowance" for the patent
Read more →SBFMSUNSHINE BIOPHARMA SIGNS AGREEMENT WITH LONZA TO MANUFACTURE ITS LEAD ANTI-CANCER COMPOUND, Adva-27a
SUNSHINE BIOPHARMA SIGNS AGREEMENT WITH LONZA TO MANUFACTURE ITS LEAD ANTI-CANCER COMPOUND, Adva-27a Montreal, Quebec, Canada -- (Marketwire) -- Sunshine Biopharma Inc. (OTCQB: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of drugs
Read more →SBFMSUNSHINE BIOPHARMA SECURES FUNDING FOR ITS Adva-27a ANTICANCER COMPOUND FROM DUTCHESS OPPORTUNITY FUND II
SUNSHINE BIOPHARMA SECURES FUNDING FOR ITS Adva-27a ANTICANCER COMPOUND FROM DUTCHESS OPPORTUNITY FUND II Montreal, Quebec, Canada -- (MARKETWIRE) -- Sunshine Biopharma, Inc. (OTCQB: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of
Read more →SBFMSunshine Biopharma Aims to Follow in Herceptin's Footsteps
MONTREAL, Aug. 10, 2011 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTCBB:SBFM) - Aggressive breast cancer has been traced to two key genetic culprits: the HER2 and TOP2 genes. Roche's Herceptin drug is the standard of care for HER2 positive patients, but there is currently no t
Read more →SBFMSunshine Biopharma Looking to Mimic Roche's Billion Dollar Cancer Drug Success
MONTREAL, July 27, 2011 (GLOBE NEWSWIRE) -- Last year, over 260,000 new cases of breast cancer (invasive and in situ combined) were diagnosed in women in the United States. Over the course of a woman's lifetime, the odds are greater than 12 percent - or 1 out of every 8 - that sh
Read more →SBFMSUNSHINE BIOPHARMA ENTERS INTO CLINICAL TRIALS AGREEMENT
SUNSHINE BIOPHARMA ENTERS INTO CLINICAL TRIALS AGREEMENT WITH THE JEWISH GENERAL HOSPITAL Montreal, Quebec, Canada -- (Canada Newswire) -- Sunshine Biopharma, Inc. (OTCBB Ticker Symbol: SBFM) a development stage pharmaceutical company focused on the research, development and co
Read more →SBFMSUNSHINE BIOPHARMA AND BINGHAMTON UNIVERSITY (STATE UNIVERSITY OF NEW YORK) ENTER INTO RESEARCH AGREEMENT
SUNSHINE BIOPHARMA AND BINGHAMTON UNIVERSITY (STATE UNIVERSITY OF NEW YORK) ENTER INTO RESEARCH AGREEMENT Parties to Work Together for Clinical Studies on Breast and Prostate Cancer Drug Montreal, Quebec, Canada-(Canada Newswire)-Sunshine Biopharma, Inc. (OTCBB Ticker Symbol:
Read more →SBFMMountain West Business Solutions Acquires Sunshine Biopharma Littleton, CO (date) Mountain West Business Solutions, Inc. (OTCBB:MWBN) today announced that it has acquired Sunshine Biopharma, Inc., a Colorado Corporation.
Mountain West Business Solutions Acquires Sunshine Biopharma Littleton, CO (date) Mountain West Business Solutions, Inc. (OTCBB:MWBN) today announced that it has acquired Sunshine Biopharma, Inc., a Colorado Corporation. The acquisition was in exchange for the issuance of 21,962
Read more →Competitive Position
How SBFM ranks across every disease it competes inCompetitive Position is a premium feature
See how SBFM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial